H.R. 2335: Stop Tampering of Prescription Pills Act of 2015

Before you vote › Federal bills

H.R. 2335: Stop Tampering of Prescription Pills Act of 2015

114th Congress · introduced 2015-05-14 · Health · Latest: Referred to the Subcommittee on Health.

federal

Save to my notebook What does this mean? Print

Official title

Stop Tampering of Prescription Pills Act of 2015

Plain summary

Stop Tampering of Prescription Pills Act of 2015 This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to deny approval to a new oral opioid (a drug with effects similar to opium, such as morphine) that does not have properties that make the drug significantly more difficult to abuse if an abuse-deterrent drug containing the same opioid is available. The FDA may approve an opioid drug that is not abuse-deterrent if approval is necessary to prevent or alleviate a drug shortage or to address a significant unmet public health need. To be approved by the FDA, a generic version of an abuse-deterrent brand name drug must be at least comparably abuse-deterrent and its active components must not differ in any material respect from the brand name drug. An approved generic drug is not bioequivalent to, and does not have the same therapeutic effect as, a brand name drug that becomes abuse-deterrent unless the generic drug is at least comparably abuse-deterrent. Approval of a generic oral opioid is withdrawn if the brand name drug is not abuse-deterrent and not available and there is an approved abuse-deterrent drug available that contains the same opioid in the same dose. Approval of an oral opioid is withdrawn if the drug is not abuse-deterrent and there is an approved abuse-deterrent drug available that contains the same opioid. Withdrawal of approval may be waived by the FDA for a drug intended for a special needs population. The FDA must delay withdrawal to give the drug sponsor an opportunity to obtain approval for an abuse-deterrent formulation of the drug.

Congressional Research Service summary (Introduced in House), quoted unchanged (nonpartisan). Read the source.

What a vote does

PSI Sci description of the legislative step (not an opinion).

The strongest published arguments

Alternatives

Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.

How did my representative vote? · This bill's floor votes

Officials and money

Sponsor: Rep. Keating, William R. [D-MA-9] · 9 cosponsors

Cost estimate: No cost estimate published yet.

Cosponsors on this site

Harold Rogers (R-KY), Stephen F. Lynch (D-MA), Robert B. Aderholt (R-AL), Vern Buchanan (R-FL), James P. McGovern (D-MA), Janice D. Schakowsky (D-IL), Katherine M. Clark (D-MA)

Sponsor's campaign money: Rep. Keating, William R. [D-MA-9] reported raising $553,690 (2025–2026). Details. Shown for context only; it does not mean any donor supported this bill.

No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.

Sources

• Congressional Research Service summary (Introduced in House)
• Congress.gov
• Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-114hr2335.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/114/hr>

Record fed-us-cong114-hr2335 · catalog fed-us-congress-bills-cong114 · updated 2026-11-15 by psicol fed-bills-cong114